

## Corrigendum: Portal vein thrombosis – a primer for the general physician

**Authors:** Mohammad Haris<sup>A</sup> and Jecko Thachil<sup>B</sup>

**Authors:** <sup>A</sup>medical student, University of Manchester, Manchester, UK; <sup>B</sup>consultant haematologist, Manchester Royal Infirmary, Manchester, UK

*Clinical Medicine* 2016;17:212–9

Mohammad Haris' name was published with the incorrect spelling. The correct spelling is printed above.

## Corrigendum: Drug therapy in anticoagulation: which drug for which patient?

**Authors:** Carolyn M Millar<sup>A</sup> and Mike A Laffan<sup>B</sup>

**Authors:** <sup>A</sup>clinical senior lecturer, Imperial College, London, UK and consultant haematologist, Imperial College Healthcare NHS Trust, London, UK; <sup>B</sup>professor of haemostasis and thrombosis, Imperial College, London, UK and honorary consultant in haematology, Imperial College Healthcare NHS Trust, London, UK

*Clinical Medicine* 2016;17:233–44

There were errors in the drug doses published in Table 1 and Table 5.

In Table 1, the correct dose of edoxaban should have been listed as 60 mg od<sup>4</sup> for NVAf and 60 mg od (following  $\geq 5$  days LMWH)<sup>4</sup> for VTE; the correct dose for rivaroxaban in ACS is 2.5 mg bd, not 2.5 mg od as originally listed.

In Table 5, the correct dose for dabigatran is 110 mg bd and the correct standard dose for rivaroxaban is 20 mg od.

The corrected tables are published below.

There was an omission in Table 2 – the confidence interval for the primary endpoint SSE for edoxaban was 97.5%.